Tom Wilton
About Tom Wilton
Tom Wilton is the Chief Business Officer at Carisma Therapeutics, known for his extensive experience in the pharmaceutical and biotechnology industries, including significant roles at LogicBio Therapeutics and the University of Pennsylvania’s Gene Therapy Program.
Tom Wilton Career Overview
Tom Wilton currently serves as the Chief Business Officer at Carisma Therapeutics, a position he has held since September 2019. Wilton brings over 20 years of experience in the pharmaceutical and biotechnology industry, significantly contributing to business strategy and development in various organizations. His extensive career spans multiple leadership roles and noteworthy achievements, particularly in the realm of gene therapy and rare diseases.
Tom Wilton Previous Roles
Before joining Carisma Therapeutics, Tom Wilton held the position of Chief Business Officer at LogicBio Therapeutics, Inc. During his tenure, he was responsible for leading strategy, business development, and intellectual property efforts, supporting the company through a successful initial public offering. Additionally, he served as the Chief Business Officer for The University of Pennsylvania’s Gene Therapy Program, facilitating multiple partnerships that helped expand the program to over 250 employees.
Tom Wilton Pharmaceutical Industry Experience
Tom Wilton began his career at GlaxoSmithKline (GSK), where he was instrumental in establishing the Rare Disease Business Unit. His career at GSK laid the foundation for his subsequent roles in the biotechnology and pharmaceutical sectors, where he has consistently been involved in strategic initiatives and operational growth.
Tom Wilton Education
Tom Wilton holds a Bachelor of Science (BS) degree from the University of London, a Master of Arts (MA) degree from the University of Leeds, and a Master of Science (MS) degree from Brunel University. His diverse educational background has equipped him with the knowledge and skills necessary for his impactful career in the pharmaceutical and biotechnology industries.